Citi analyst Joanne Wuensch raised the firm’s price target on Intuitive Surgical to $560 from $512 and keeps a Buy rating on the shares. The analyst calls Q2 “another wild ride” for the medical technology sector. The earnings prints brought “several eye-opening and frankly shocking deliveries, changes to guidance, and stock price reactions,” the analyst tells investors in a research note. Citi expects an “interesting” September broker season, and looks for updated management commentary on patient volumes, capital equipment, and China. It reiterated its top picks of Boston Scientific (BSX), GE HealthCare (GEHC), and Insulet (PODD), looking for acceleration moving through the remainder of 2024 and into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical price target raised to $515 from $475 at RBC Capital
- Intuitive Surgical upgraded to Buy from Neutral at Redburn Atlantic
- Intuitive Surgical Enhances Board with Strategic Appointment
- Intuitive President David J. Rosa Appointed to Intuitive Board of Directors
- Intuitive Surgical appoints Rosa to board of directors